Wall Street analysts expect VIVUS, Inc. (NASDAQ:VVUS) to post earnings per share of ($1.10) for the current quarter, according to Zacks. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS posted earnings of ($0.60) per share in the same quarter last year, which suggests a negative year over year growth rate of 83.3%. The firm is expected to announce its next earnings report on Thursday, November 1st.
According to Zacks, analysts expect that VIVUS will report full-year earnings of ($4.40) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($5.70) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow VIVUS.
VIVUS (NASDAQ:VVUS) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.08). The business had revenue of $14.96 million for the quarter.
A number of research analysts have commented on the stock. ValuEngine upgraded shares of VIVUS from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research upgraded shares of VIVUS from a “sell” rating to a “hold” rating in a research note on Thursday, September 20th.
A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC lifted its position in shares of VIVUS, Inc. (NASDAQ:VVUS) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,273,800 shares of the biopharmaceutical company’s stock after acquiring an additional 423,100 shares during the quarter. Renaissance Technologies LLC owned 7.79% of VIVUS worth $5,833,000 at the end of the most recent quarter.
NASDAQ VVUS opened at $3.41 on Tuesday. The firm has a market capitalization of $37.92 million, a price-to-earnings ratio of -1.18 and a beta of 0.58. VIVUS has a one year low of $3.30 and a one year high of $9.90.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Further Reading: Trading Strategy Examples and Plans
Get a free copy of the Zacks research report on VIVUS (VVUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.